Baiteng Zhao

Co-founder and former Chairman and CEO at ProfoundBio

Speaker

Dr. Zhao co-founded ProfoundBio in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab for $1.8 billion in May 2024. Prior to this, he worked at Seagen and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug candidates. Before joining Seagen in 2009, he worked in the Clinical Pharmacokinetics department Merck (MRL, USA). Dr. Zhao graduated with a bachelor's degree in biology from Peking University, earned his Ph.D. from the College of Pharmacy at the University of Texas at Austin, and completed his postdoctoral research at the State University of New York at Buffalo.